George O'Brien
FDA publishes final guidance on ANDA/505(b)(2) NDA pathways
Focus on Regulation ·
FDA’s Bendeka decision reverses approvals of Treanda generics
Focus on Regulation ·
Four new FDA guidances and proposed rule advance biosimilars policy framework
Focus on Regulation ·